Target type: biologicalprocess
Any process that modulates the rate, frequency or extent of collagen catabolism. Collagen catabolism is the proteolytic chemical reactions and pathways resulting in the breakdown of collagen in the extracellular matrix. [GOC:BHF, GOC:dph, GOC:tb]
The regulation of collagen catabolic process involves a complex interplay of enzymes, signaling pathways, and regulatory factors that control the breakdown of collagen, a major structural protein in the extracellular matrix.
**Enzymes involved in collagen degradation:**
* **Matrix metalloproteinases (MMPs):** A family of zinc-dependent endopeptidases that play a crucial role in the degradation of collagen and other extracellular matrix components. MMPs are secreted as inactive pro-enzymes (zymogens) and activated by specific proteases.
* **Cathepsins:** A family of lysosomal cysteine proteases that contribute to collagen degradation, particularly in the lysosomes of cells.
* **ADAMTSs (A Disintegrin and Metalloproteinase with Thrombospondin Motifs):** A family of metalloproteinases with diverse functions, including the cleavage of collagen and other extracellular matrix components.
**Regulation of collagen catabolic process:**
* **Growth factors and cytokines:** Factors such as transforming growth factor-beta (TGF-beta) and interleukin-1 (IL-1) can stimulate collagen breakdown by inducing the expression and activation of MMPs.
* **Mechanical stress:** Mechanical forces can trigger the expression and activation of MMPs, contributing to the breakdown of collagen in tissues under stress.
* **Hormones:** Hormones like glucocorticoids can stimulate the expression of MMPs and contribute to collagen degradation.
* **Extracellular matrix components:** The composition and organization of the extracellular matrix can influence the activity of MMPs and other collagen-degrading enzymes.
* **Inhibitors:** Tissue inhibitors of metalloproteinases (TIMPs) are a family of proteins that specifically inhibit the activity of MMPs, thereby regulating collagen breakdown.
**Cellular processes involved:**
* **Endocytosis:** Cells can internalize collagen fragments through endocytosis, where they are degraded by lysosomal enzymes.
* **Autophagy:** This process involves the degradation of cellular components, including collagen, within lysosomes.
**Significance of collagen catabolic process:**
* **Tissue remodeling and repair:** Collagen breakdown is essential for tissue remodeling during development, wound healing, and tissue repair.
* **Pathological conditions:** Dysregulation of collagen catabolism can contribute to various pathological conditions, such as arthritis, cancer, and fibrosis.'
"
Protein | Definition | Taxonomy |
---|---|---|
Prolyl endopeptidase FAP | A prolyl endopeptidase FAP that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q12884] | Homo sapiens (human) |
Integrin beta-1 | An integrin beta-1 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P05556] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
haloperidol | haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety. Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) | aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol | antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist |
1,3-ditolylguanidine | 1,3-ditolylguanidine: structure given in first source; a selective ligand for the sigma binding sites in the brain | toluenes | |
tirofiban | tirofiban : A member of the class of piperidines that is L-tyrosine in which a hydrogen attached to the amino group is replaced by a butylsulfonyl group and in which the hydrogen attached to the phenolic hydroxy group is replaced by a 4-(piperidin-4-yl)butyl group. Tirofiban: Tyrosine analog and PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX antagonist that inhibits PLATELET AGGREGATION and is used in the treatment of ACUTE CORONARY SYNDROME. | L-tyrosine derivative; piperidines; sulfonamide | anticoagulant; fibrin modulating drug; platelet glycoprotein-IIb/IIIa receptor antagonist |
arginyl-glycyl-aspartic acid | arginyl-glycyl-aspartic acid: amino acid sequence of basic unit of widespread cellular recognition system | oligopeptide | |
arginyl-glycyl-aspartyl-serine | arginyl-glycyl-aspartyl-serine: corresponds to cell attachment site of fibronectin; located near carboxyl-terminal region of alpha-chain of fibrinogen; inhibits platelet aggregation & fibrinogen binding to activated platelets | ||
glycyl-arginyl-glycyl-aspartyl-serine | glycyl-arginyl-glycyl-aspartyl-serine: synthetic peptide from fibronectins; inhibits experimental metastasis of murine melanoma cells | ||
n-carbobenzoxyglycyl-prolyl-4-methylcoumarinyl amide | N-carbobenzoxyglycyl-prolyl-4-methylcoumarinyl amide: fluorogenic substrate for post-proline cleaving enzyme | ||
d-arg-gly-asp-trp | arginyl-glycyl-aspartyl-tryptophan: a synthetic RGD-containing peptide | ||
l 738167 | L 738167: structure in first source | ||
cilengitide | Cilengitide: an alphaVbeta3 integrin antagonist that paralyzes cancer cells | oligopeptide | |
l 734217 | L 734217: fibrinogen receptor antagonist; structure given in first source | ||
cyclopamine | piperidines | glioma-associated oncogene inhibitor | |
arginyl-glycyl-aspartyl-phenylalanine | |||
sitagliptin | sitagliptin : A triazolopyrazine that exhibits hypoglycemic activity. | triazolopyrazine; trifluorobenzene | EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; environmental contaminant; hypoglycemic agent; serine proteinase inhibitor; xenobiotic |
vildagliptin | amino acid amide | ||
talabostat | talabostat: an antineoplastic agent; structure in first source | ||
cyclic(arg-gly-asp-d-phe-val) | |||
mk-0429 | |||
mocetinostat | mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11). mocetinostat: undergoing phase II clinical trials for treatment of cancer | aminopyrimidine; benzamides; pyridines; secondary amino compound; secondary carboxamide; substituted aniline | antineoplastic agent; apoptosis inducer; autophagy inducer; cardioprotective agent; EC 3.5.1.98 (histone deacetylase) inhibitor; hepatotoxic agent |
tr 14035 | N-(2,6-dichlorobenzoyl)-4-(2',6'-bismethoxyphenyl)phenylalanine: TR-14035 is the (L)-isomer; an antagonist of both alpha4beta1 and beta7 integrins; structure in first source | ||
bio 1211 | BIO 1211: integrin alpha4beta1 inhibitor; structure in first source | ||
linagliptin | linagliptin : A xanthine that is 7H-xanthine bearing (4-methylquinazolin-2-yl)methyl, methyl, but-2-yn-1-yl and 3-aminopiperidin-1-yl substituents at positions 1, 3, 7 and 8 respectively (the R-enantiomer). Used for treatment of type II diabetes. Linagliptin: A purine and quinazoline derivative that functions as an INCRETIN and DIPEPTIDYL-PEPTIDASE IV INHIBTOR. It is used as a HYPOGLYCEMIC AGENT in the treatment of TYPE II DIABETES MELLITUS. | aminopiperidine; quinazolines | EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; hypoglycemic agent |
kyp 2047 | |||
bms 477118 | adamantanes; azabicycloalkane; monocarboxylic acid amide; nitrile; tertiary alcohol | EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; hypoglycemic agent | |
alogliptin | alogliptin : A piperidine that is 3-methyl-2,4-dioxo-3,4-dihydropyrimidine carrying additional 2-cyanobenzyl and 3-aminopiperidin-1-yl groups at positions 1 and 2 respectively (the R-enantiomer). Used in the form of its benzoate salt for treatment of type 2 diabetes. alogliptin: structure in first source | nitrile; piperidines; primary amino compound; pyrimidines | EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; hypoglycemic agent |
gosogliptin | amino acid amide | ||
anagliptin | anagliptin: anagliptin hydrochloride salt is the active compound | amino acid amide | |
mk-3102 | pyrrolopyrazole |